Shanghai, China and Boston, MA., – September 28, 2025 – NeuShen Therapeutics (the "Company") announced today that it will present two posters at Neuroscience 2025 in San Diego, California, from November 15-19. The annual conference, hosted by the Society for Neuroscience (SfN), is the world's leading platform for showcasing latest advances in CNS research.

Poster 1: Preclinical characterization of M4 muscarinic receptor positive allosteric modulator NS-136
Presentation Time: November 19, 2025, 14:00-15:00
Presentation Number: PSTR427.02
Session: Schizophrenia: Translational Studies and Experimental Therapeutics
Location/Room: SDCC Halls B-H

The Company has conducted systematic preclinical characterization and translational study of NS-136, an M4 muscarinic receptor positive allosteric modulator, detailing its physicochemical properties and mechanism of action. The data validated the efficacy of NS-136 in alleviating psychiatric symptoms through various behavioral models and demonstrated a good safety profile without sides effects such as extrapyramidal symptoms.

In a completed Phase 1 clinical trial on healthy subjects (including both adults and elderly individuals), NS-136 exhibited an excellent safety and pharmacokinetic profile. All reported adverse events were mild and self-resolving, with a maximum daily dose of 120mg. Pharmacokinetic exposure increased subproportionally with dose, and individual pharmacokinetic variability was low, indicating ideal druggability. Detailed clinical data will be presented at upcoming conferences. Based on preclinical and Phase 1 data, the Company plans to initiate multiple Phase 2 trials for NS-136 in both China and the U.S.

Poster 2: Discovery of novel 5-HT2A receptor partial agonist without hallucinogenic effects
Presentation Time: November 18, 2025, 13:00-14:00
Presentation Number: PSTR355.09
Session: Translational Studies of Hallucinogens and Related Compounds
Location/Room: SDCC Halls B-H

The Company will also present preclinical data for its proprietary neuroplasticity modulator, NS-079. In recent years, neuroplasticity modulators have shown potential in treating mood disorders, but their clinical use has been limited by safety concerns, such as hallucinogenic effects. The Company has developed two compounds targeting the 5-HT2A and NMDA signaling pathways, aimed at exploring novel treatment strategies for treatment-resistant depression through distinct biological mechanisms.

NS-079, a novel non-hallucinogenic 5-HT2A receptor partial agonist, provides rapid and sustained antidepressant effects while effectively minimizing hallucinogenic risks through its innovative molecular design, potentially offering a safe, convenient and fast-acting treatment option for patients with treatment-resistant depression. NS-079 is currently undergoing IND-enabling studies, with clinical development planned in the first half of 2026.

"The expertise and execution of our team form the foundation for building our globally competitive pipeline,” Dr. Joan Shen, founder and CEO of the Company, commented. “We plan to highlight our programs at several upcoming conferences to continue to showcase our R&D capabilities in CNS. We look forward to having in-depth discussions with experts from around the world at Neuroscience 2025."

The Company continues to accelerate its pipeline expansion in the field of psychiatric and neurological diseases while actively seeking global partnerships. NeuShen Therapeutics is committed to advancing differentiated drug candidates into clinical stages, with the goal of creating a world-leading platform for innovative CNS drug development.

About NeuShen Therapeutics

NeuShen Therapeutics is a clinical-stage global biotechnology company focused on developing novel therapies for CNS disorders. Operating from Shanghai and Boston, NeuShen boasts a world-class R&D team in the CNS field and is advised by an esteemed board of scientific advisors. The company has established a robust and competitive pipeline of potentially best-in-class drug candidates, with multiple key compounds currently in clinical development.